Parents across several countries thought they had found a safe route to parenthood, until doctors spotted the same rare cancer clue.
What began as a success story of modern fertility medicine has turned into a worrying case study, after a prolific Danish sperm donor was found to carry a rare genetic mutation linked to childhood cancers, potentially affecting nearly 200 children worldwide.
A prolific donor, dozens of clinics, 14 countries
Denmark has quietly become a global hub for sperm donation. Its large commercial banks ship frozen samples to fertility clinics across Europe and beyond, offering detailed donor profiles and, in theory, robust medical screening.
Between 2006 and 2022, one anonymous donor, known under the pseudonym “Kjeld”, supplied sperm to 67 clinics in 14 different countries through the European Sperm Bank, one of the largest facilities of its kind.
His donations led to an estimated 197 births, including 99 children in Denmark alone, according to Danish public broadcaster DR.
For many couples and single parents facing infertility, those donations meant long-awaited pregnancies and healthy babies. Years later, paediatricians began to notice something disturbing: a handful of these children developed cancers, and genetic testing kept pointing in the same direction.
How the alarm was raised
The first warning came in April 2020, when the sperm bank was notified that a child conceived with “Kjeld’s” sperm had been diagnosed with cancer and was found to carry a mutation on the TP53 gene.
At the time, this was treated as a serious but isolated case. The bank registered the information, but the full picture had not yet emerged. Then, three years later, another child, conceived with the same donor’s sperm, was diagnosed with cancer and was found to have a very similar TP53 mutation.
This repeat finding prompted a deeper investigation. The sperm bank arranged more detailed genetic analysis of stored samples from the donor.
The tests confirmed a rare TP53 mutation in a portion of the donor’s sperm cells, a defect that had escaped initial screening.
➡️ Unexpected discovery: thousands of nests found beneath Antarctic ice
➡️ What if grey hair is a natural anti‑cancer shield? Here’s what the science says
➡️ Hairstyles after 50: the best cuts to look younger in 2026
➡️ Mystery of the Virgin Mary’s bloody tears: DNA analysis reveals startling conclusions
➡️ Few people know Japan controls 95% of this material vital to Nvidia’s AI chips, thanks to Ajinomoto
➡️ Germany pulls off a breakthrough in quantum teleportation, paving the way for tomorrow’s internet
By the time the anomaly was confirmed, his sperm had already been distributed to clinics in multiple countries over a period of 16 years.
What is TP53 and why does it matter?
TP53 is one of the most studied genes in cancer biology. It gives the body instructions to make a protein called p53, often referred to by researchers as the “guardian of the genome”.
- p53 checks the DNA of cells for damage
- it can pause cell division to allow repair
- if the damage is beyond repair, it can trigger cell death
By forcing badly damaged cells to self-destruct, p53 helps prevent them from turning into cancer. When the TP53 gene is mutated, this defence system can fail, increasing the risk of tumours forming early in life.
Inherited TP53 mutations are best known in a condition called Li-Fraumeni syndrome, where families see repeated cancers across generations, often in childhood or early adulthood. In this Danish case, things are more complicated.
A rare and unusual kind of mutation
The European Sperm Bank stated that the donor did not show signs of cancer himself and that the mutation was not detected in his blood or other tissue samples.
The mutation appears to be confined to a fraction of his sperm cells, a pattern called “mosaicism”, meaning only some of his reproductive cells carry the defect.
This has several consequences:
- the donor can be healthy, because most of his body cells are normal
- only a proportion of his sperm carry the mutation
- each pregnancy has a chance, but not a certainty, of inheriting the faulty gene
So while a number of children conceived with his sperm have developed cancer, many others are expected to be unaffected. The exact number of children who inherited the TP53 mutation is not known publicly.
Why standard screening missed the problem
Sperm banks typically screen donors with questionnaires, physical examinations, blood tests for infections, and, in some cases, targeted genetic tests for known conditions such as cystic fibrosis or certain chromosomal abnormalities.
Testing every donor for all possible rare mutations is not currently feasible. Full genome sequencing remains expensive and can generate uncertain findings that are difficult to interpret or communicate to families.
Because the TP53 variant in this case was both rare and previously undescribed, it would not have appeared on routine genetic panels aimed at common, well-characterised mutations.
Mosaicism adds another layer of complexity. If only some sperm cells carry a mutation, a blood test from the donor can easily return as “normal”, even though the sperm contains a risky variant. Detecting such patterns reliably would require more sophisticated and costly testing strategies.
Potential implications for families and clinics
For parents who used this donor, the news is understandably frightening. Some have children who are already facing cancer treatment. Others have apparently healthy youngsters, but are now living with uncertainty about their genetic risk.
Sperm banks and clinics must now decide how to contact affected families, especially those living abroad or using anonymous donation arrangements. Ethical questions follow quickly: how much should be disclosed, how fast, and by whom?
At a systemic level, the case raises concerns about donor limits. Some countries cap the number of families or children that can be linked to a single donor. In Denmark, the rules have historically been more permissive, which increases the potential impact when a problem is identified later.
| Issue | Current practice | Possible change after this case |
|---|---|---|
| Number of children per donor | Higher limits in some countries | Stricter caps to reduce risk clusters |
| Genetic screening | Panels for common conditions | Discussion of broader sequencing for high-use donors |
| Follow-up | Limited long-term tracking | Systems to report and share serious health events |
Infertility, demand for donors and hidden risks
Infertility affects roughly 15–25% of couples in France after a year of trying to conceive, according to a 2019 Inserm report, and similar ranges are reported in other European countries.
Causes vary significantly. In women, ovulation disorders, damaged fallopian tubes, or uterine problems can block conception. In men, low sperm count, poor sperm quality, hormonal imbalances, varicocele, infections, or genetic anomalies can all play a role.
This unmet need drives strong demand for donor sperm, especially from countries seen as having rigorous medical systems. Danish donors, often portrayed as healthy, well-screened, and well-educated, are particularly sought after.
The higher the demand for a small group of popular donors, the larger the number of children that can be affected when a hidden genetic issue comes to light.
What affected families may face next
For families who know their child was conceived with this donor’s sperm, genetic counselling becomes crucial. A typical pathway could include:
- confirming whether the child carries the TP53 mutation
- discussing the actual level of cancer risk for that specific variant
- planning tailored monitoring, such as more frequent check-ups or imaging
- offering psychological support to parents and, when age-appropriate, to the child
Not every TP53 mutation carries the same risk level. Some variants are strongly linked to aggressive, early-onset cancers; others have weaker or less well-understood effects. Since this specific mutation has not been described previously, doctors may need time and pooled international data to understand its impact.
Key terms and practical questions for would-be parents
People considering donor sperm often confront technical language at the worst possible time, when emotions are already high. A few concepts from this case can help frame questions to clinics:
- Mosaicism: when only some cells in a person’s body carry a mutation. This means standard blood tests can miss defects present only in eggs or sperm.
- Genetic panels: sets of genes tested for known, common mutations. They do not catch every possible rare variant.
- Reporting systems: mechanisms through which clinics and banks share serious health outcomes from donor-conceived children, so patterns can be spotted earlier.
Prospective parents can ask how many children a donor is expected to have, what level of genetic testing is performed, and whether the bank participates in any international registries to track serious medical issues linked to donors.
No screening system can remove all risk. Yet this Danish case suggests that tighter donor limits, better reporting across borders, and more nuanced genetic testing policies for heavily used donors could lessen the impact of rare but consequential mutations in future.